로딩 중…
지수 로딩 중…
진시스템
363250· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩3,685-1.34%
2026-06-19
Price Chart
진시스템-58.27%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 31.35B KRW |
| Revenue | 647.1M KRW |
| Net Income | -14.45B KRW |
| Total Assets | 15.65B KRW |
| Net Assets | 9.40B KRW |
| Employees | 69 |
| Value | |
| P/B | 3.33x |
| P/S | 48.45x |
| FCF Yield | -21.95% |
| Profitability | |
| ROE | -153.66% |
| ROA | -92.31% |
| Op. Margin | -1497.57% |
| Revenue Growth | 419.00% |
| Financial Health | |
| Debt Ratio | 166.46% |
| Total Debt | 3.74B KRW |
| FCF | -6.88B KRW |
| Cash | 4.35B KRW |
| Current Ratio | 2.62x |
| Performance | |
| 1Y Return | -58.27% |
| 1M Return | -14.90% |
| From 52W High | -61.81% |
| 1Y MDD | -68.00% |
| Trading | |
| Volume | 19,639 shares |
| Foreign Own. | 2.31% |
| Per Share | |
| EPS | -1,645 KRW |
| BPS | 1,262 KRW |
Company Info
GeneSystem was established in 2010 to commercialize a rapid PCR technology-based platform and was listed on KOSDAQ in 2021. The company specializes in molecular diagnostic equipment and diagnostic kits, expanding its business primarily in Europe and Asia, and experienced growth in developing country markets post-2020 pandemic. It pursues market entry by diversifying rapid platform technology-based testing solutions and employing a two-track B2B strategy, continuously releasing respiratory disease diagnostic content for the post-COVID era to drive global market adoption. Headquartered in Yuseong-gu, Daejeon, GeneSystem was founded in 2010.